Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3265 | Surge Index Wiki | 0.45 |
drug593 | COVID visitation restrictions Wiki | 0.45 |
drug3585 | Valproate Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug2749 | Quetiapine Wiki | 0.45 |
drug764 | Chlorpromazine Wiki | 0.45 |
drug1029 | Dexmedetomidine Injectable Product Wiki | 0.45 |
drug618 | COVID-19 antibodies testing Wiki | 0.45 |
drug616 | COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki | 0.32 |
drug146 | Acebilustat Wiki | 0.32 |
drug685 | Camostat Wiki | 0.20 |
drug3191 | Standard of Care Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D020196 | Trauma, Nervous System NIH | 0.45 |
D013896 | Thoracic Diseases NIH | 0.45 |
D009421 | Nervous System Malformations NIH | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D000071257 | Emergence Delirium NIH | 0.45 |
D001927 | Brain Diseases NIH | 0.40 |
D000013 | Congenital Abnormalities NIH | 0.32 |
D006331 | Heart Diseases NIH | 0.17 |
D006333 | Heart Failure NIH | 0.15 |
D016638 | Critical Illness NIH | 0.11 |
D007249 | Inflammation NIH | 0.08 |
D002318 | Cardiovascular Diseases NIH | 0.07 |
D011024 | Pneumonia, Viral NIH | 0.05 |
D013577 | Syndrome NIH | 0.04 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
D055371 | Acute Lung Injury NIH | 0.04 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
D011014 | Pneumonia NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000707 | Abnormality of the nervous system HPO | 0.45 |
HP:0001298 | Encephalopathy HPO | 0.40 |
HP:0001635 | Congestive heart failure HPO | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.07 |
HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 5 clinical trials
A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation. Measurements of respiratory performance and quantification of cellular and molecular inflammatory mediators. The primary outcome will be the avoidance of mechanical ventilation with secondary outcomes duration of mechanical ventilation, avoidance of delirium after sedation and association of mediators of inflammation to outcomes. Outcomes will be compared to a matched historical control (no DEX) series
Description: (Presence/Absence) requirement of mechanical ventilation
Measure: Mechanical ventilation Time: expected within first three days (non conclusive due to lack of evidence yet)Description: Duration of mechanical ventilation if it is required (hours from the start)
Measure: Duration of mechanical ventilation Time: expected within first seven days (non conclusive due to lack of evidence yet)Description: Delirium criteria as defined in DSM-4
Measure: Delirium on recovery from sedation Time: First 24 hours after retiring dexmedetomidine sedationDelirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.
Description: Assessment of neurocognitive impairment using validated tools
Measure: Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19 Time: Day 90Description: Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples
Measure: Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19 Time: Change from baseline biomarker levels at day 28Description: Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)
Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 Time: Day 90Description: Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)
Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 Time: Change from baseline IQCODE results at day 90Description: Assessment of the overall quality of life using validated tests [e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)]
Measure: Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge Time: Day 90Description: Cumulative days in hospital
Measure: Length of hospital stay in patients with COVID-19 compared to patients without COVID-19 Time: 1 yearDescription: Survival after 90 days
Measure: 90-day survival in patients with COVID-19 compared to patients without COVID-19 Time: Day 90The primary purpose of this research is to determine whether Valproate alone, and in combination with Quetiapine, lowers confusion and agitation in persons with severe Corona Virus Disease (COVID)19 pneumonia during weaning from the breathing machine (ventilator). Though Valproate and Quetiapine are often given to persons with severe confusion with agitation, the purpose of this small research study is specifically for: a) persons infected with COVID 2019 on a ventilator whose agitation is not responding to the usual medications (like dexmedetomidine), and b) to reduce the time persons are treated with dexmedetomidine, which requires continuous close monitoring in an ICU.
Description: Richmond Agitation Sedation Scale (RASS) score ranges from +4 (combative) to 0 (alert & calm) to -5 (unarousable).
Measure: Change from baseline RASS score of +3 or greater Time: Baseline, Day 7Description: Total dose of dexmedetomidine administered will be reported from baseline RASS score of +3 or greater.
Measure: Total dose of dexmedetomidine administered Time: Day 7Description: Incidence of Treatment Emergent Adverse Events will include: QTc duration > 470 msecs. Increase in Liver Function Tests to a Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. Suicidality reported as having a score of moderate or high risk using the Columbia-Suicide Severity Rating Scale Screening (C-SSRS). C-SSRS is a calculated risk assessment tool that scores suicidality from no risk to high risk.
Measure: Incidence of Treatment Emergent Adverse Events Time: Day 7Patients are part of a family network. When any person in a family becomes critically unwell and requires the assistance of an Intensive Care Unit (ICU), this has an impact on all members of that family. COVID-19 changed visiting for all patients in hospitals across Scotland. It is not known what effect these restrictions will have on patients' recovery, nor do we understand the impact it may have on their relatives or staff caring for them. This study will look at the implications of the visiting restrictions as a consequence of the COVID-19 pandemic upon patients without COVID-19 who are in the cardiothoracic ICU. It will also explore the impact of these restrictions on them, their relatives and staff. This study will be carried out within a single specialised intensive care unit in Scotland using mixed methods. The first arm of this study will use retrospective data that is routinely collected in normal clinical practice. The investigators will compare patient outcomes prior to COVID-19 with outcomes following the implementation of COVID-19 visiting restrictions. The aim is to establish if the restrictions on visiting has an impact on the duration of delirium. Delirium is an acute mental confusion and is associated with longer hospital stays and worse outcomes in this patient group. The second arm of this study involves semi-structured interviews with patients, relatives and staff that will allow deeper exploration of the issues around current visiting policy. The interviews will last approximately 1 hour and will address these issues. They will then be transcribed word for word and analysed using grounded theory, meaning the theories will develop from the data as it is analysed.
Description: Number of days patient found to have delirium using the Confusion Assessment Method for the ICU (CAM-ICU)
Measure: Duration of delirium Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.Description: CAM-ICU
Measure: Incidence of delirium Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.Description: Days
Measure: Length of critical care stay Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.Description: Days
Measure: Length of hospital stay Time: From the date of admission to the hospital until discharge from the hospital or death, whichever came first, up to 12 months.Description: Days
Measure: Length of time ventilated Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.Description: Semi structured interviews
Measure: Exploring the experiences of patients, relatives and staff of the visitation restrictions during the COVID-19 pandemic Time: 18 monthsThe SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.
Description: Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2
Measure: Dosage of biomarkers typically explored in intensive care unit delirium Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL
Measure: Dosage of neuronal injury markers Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: CAM-ICU (Confusion Assessment Method - Intensive Care Unit) scale
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: ICDSC (Intensive Care Delirium Screening Checklist) scale.
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CRS-R (Coma Recovery Scale-Revised)
Measure: Coma assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Clinical observation
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Pupilometer assessment
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Electroencephalogram : epileptic activity (spikes, spike-waves) or encephalopathy activity (triphasic waves))
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CT-scan
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: MRI
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports